| Date Filed | Type | Description |
| 07/26/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 07/26/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/26/2023 |
8-K
| Quarterly results |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/26/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, CA – April 3, 2023 – Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,586,300 additional shares of common stock. The gross proceeds to Viking from this offering are approximately $287.5 million, before deducting underwriting discounts and commissions and other estimated ..." |
|
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNDERWRITING AGREEMENT",
"LEGAL OPINION",
"Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock SAN DIEGO, CA – March 29, 2023 – Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $250.0 million. In addition, Viking has granted the underwriters a 30-day option to purchase up to 2,586,300 additional shares of its common stock on the same terms and conditions. The offering is expected to close on or about April 3, ..." |
|
| 03/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| ArrowMark Colorado Holdings LLC reports a 0% stake in VIKING THERAPEUTICS, INC. |
| 02/09/2023 |
SC 13D/A
| LIGAND PHARMACEUTICALS INC reports a 7.9% stake in Viking Therapeutics, Inc. |
| 02/08/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/26/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/26/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/27/2022 |
8-K
| Quarterly results |
|